Cardiovascular safety of febuxostat. Analysis of the CARES study
Gout is associated with the high frequency of comorbidities, among which there are cardiovascular disease and kidney diseases. In this case, cardiovascular mortality rates are in the first place among the causes of death in patients with gout and exceed the death rates in the population. This may be...
Main Author: | M. S. Eliseev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/860 |
Similar Items
-
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01) -
Microbiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiota
by: M. S. Eliseev, et al.
Published: (2022-12-01) -
The current treatment strategy for gouty arthritis
by: M. S. Petrova, et al.
Published: (2018-09-01) -
The place of febuxostat in the treatment of gout
by: A. M. Novikova, et al.
Published: (2020-09-01) -
Pharmacotherapy of gout – modern approaches and prospects
by: P. A. Lebedev, et al.
Published: (2021-08-01)